Clinical Trials Directory
We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.
In this study, people will be placed into one of two groups by chance. One group will receive a new treatment called ronde cel. The other group will receive a CAR T cell treatment that is already approved and chosen by their cancer doctor. The new treatment is made to target two parts of the cancer cells, while current treatments target only one part. People in the study must be able to stay close to the hospital for at least three weeks and come back for follow up visits so doctors can check their health.
We are doing this study to find out if an experimental drug called upadacitinib (the study drug) is a safe and effective option for people with moderate to severe hidradenitis suppurativa (HS) who did not get adequate relief from standard treatment.
We are doing this study to learn more about the sounds coming from a Doppler device when testing arteries. The recording will be used to train a computer program to compare the sounds from healthy arteries to non-healthy arteries.
We are doing this study to understand how environmental exposures may be involved in lung function. We want to find out how immune cells in the lungs are affected by irritants that are present in the environment.
We are doing this study to learn more about ATTR and its different variants and how they can can be better diagnosed, managed, and treated.
We are doing this study to find out if an experimental drug called NTLA-2001 (the study drug) is a safe and effective option for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study drug is made using the CRISPR-CaS9 gene editing system. The intent of the study drug that is being tested is to target the TTR gene and make it inactive.
We are doing this study to learn more about heart valve disease and its standard-of-care treatments, and we want to learn more about the safety and performance of the Corcym devices and accessories used for heart valve disease.